Given the mortality estimates for NORSE range from 10% to 20%, and the already dangerous condition accompanied by the modern age pandemic that has the potential to mutate and cause reinfections, a study was warranted.7,8 In this regard, a detailed observation of the clinical features, treatment, and outcomes in patients reporting new-onset refractory status epilepticus (NORSE) secondary to COVID-19 infection was conducted.